Unlock instant, AI-driven research and patent intelligence for your innovation.

Therapeutic combinations and methods of treating melanoma

A melanoma and toxin technology, applied in the field of melanoma treatment, can solve problems such as disease recurrence

Inactive Publication Date: 2014-09-10
F HOFFMANN LA ROCHE & CO AG
View PDF144 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although clinical trials revealed improved survival, improved objective response rate, and improved progression-free survival in patients treated with Vemurafenib compared to DTIC, disease relapse was likely (Nazarian R. et al., Melanomas acquire resistance to B- RAF(V600E)inhibition by RTK or N-RASupregulation.Nature Vol:468,Pages:973-977(16 December 2010))

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic combinations and methods of treating melanoma
  • Therapeutic combinations and methods of treating melanoma
  • Therapeutic combinations and methods of treating melanoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0383] Example 1: In vitro evaluation of specific cell killing by anti-ETBR ADC

[0384] In melanomas expressing a relatively low copy number of ETBR (in the case of cell line A2058 (from the American Type Culture Collection)) or a higher copy number of ETBR (in the case of cell line UACC-257X2.2) The anti-ETBR antibody-ADC candidate Hu5E9v1-ADC was evaluated in vitro on the cell line. The UACC-257X2.2 cell line is a derivative of the parental UACC-257 cell line (NCI-Frederick Cancer DCT Tumor Repository), optimized for in vivo growth. The parental UACC-257 cells were injected subcutaneously into the right side of female NCr nude mice, and a tumor was harvested and dissociated, and cultured in vitro to generate the UACC-257X1.2 cell line. The UACC-257X1.2 line was injected subcutaneously into the right side of female NCr nude mice again to try to improve the growth of the cell line. A tumor was collected from this study and adapted again to grow in vitro to generate the UACC-2...

Embodiment 2

[0388] Example 2: In vivo evaluation of specific tumor killing by anti-ETBR ADC

[0389] Based on the research described in Example 1 above, the melanoma cell lines A2058 and UACC-257X2.2 were selected as suitable models for in vivo anti-tumor activity studies representing broad ETBR expression. The UACC-257X2.2 melanoma cell line is a derivative of the parental UACC-257 melanoma cell line (National Cancer Institute (NCI)), optimized for in vivo growth. Specifically, parental UACC-257 cells were injected subcutaneously into the right side of female NCr nude mice, and a tumor was harvested and cultured in vitro to generate UACC-257X1.2 cell line. The UACC-257X1.2 line was injected subcutaneously into the right side of female NCr nude mice again to try to improve the growth of the cell line. A tumor was collected from this study and adapted again to grow in vitro to generate the UACC-257X2.2 cell line. This cell line and tumors derived therefrom express ETBR equivalent to the pa...

Embodiment 3

[0394] Example 3: Effect of BRAF inhibitor drugs on the expression level of ETBR

[0395] Evaluation of the effects of BRAF inhibitor drugs on ETBR transcripts and proteins in a variety of melanoma cells representing various genetic backgrounds of melanoma (such as BRAF mutant (V600E), BRAF wild type and RAS mutant (Q61L)). Total protein and cell surface protein) expression levels.

[0396] By adding the appropriate drug volume to the cultured cells on a 4-well plate for 24 hours, the melanoma cell line UACC-257X2.2 was treated with different concentrations of BRAF inhibitor drugs ("BRAFi") (specifically RG7204), A2058, COLO 829, IPC-298 (ATCC).

[0397] In order to determine the effect of BRAFi on ETBR and control ribosomal protein L19 (RPL19) transcript levels, the following experiment was performed. Cells treated with RG7204 for 24 hours were harvested from the plate by scraping and processed for total RNA using Qiashredder and RNeasy mini kit (79654, 74104, Qiagen, Valencia, C...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides therapeutic combinations of anti-ETBR antibodies and MAP kinase inhibitors and methods of using the same to treat melanoma.

Description

[0001] Related application [0002] This application requires U.S. Provisional Application No. 61 / 552,893 filed on October 28, 2011 and U.S. Provisional Application No. 61 / 678,978 filed on August 2, 2012 in accordance with 35 USC 119(e). Its content is included in this article. Invention field [0003] Generally speaking, the present invention relates to the treatment of melanoma by using certain combinations of antibodies and small molecule drugs. Background of the invention [0004] Melanoma is an aggressive form of skin cancer, and its incidence has recently increased worryingly (Thompson JF et al., Cutaneous melanoma in the era of molecular profiling. Lancet 2009; 374:362-5) . Although healing can be achieved by surgical removal of localized damage, advanced-stage melanoma has only a poor response to currently approved therapies. The 5-year survival rate for stage IV metastatic melanoma is approximately 10% (Thompson, Lancet 2009). New treatments (including antisense to Bcl2...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00A61K39/395A61P35/00
CPCC07K16/2869A61K39/39558A61K2039/545A61K31/437C07K16/3053A61K31/4523A61P35/00A61K2300/00
Inventor P.波拉基斯J.阿苏恩迪S.克拉克
Owner F HOFFMANN LA ROCHE & CO AG